Department of Pharmacy, Chinese PLA General Hospital, Beijing, China; Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Beijing Institute of Pharmacology and Toxicology, Beijing, China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:1-5. doi: 10.1016/j.jchromb.2013.10.027. Epub 2013 Nov 1.
Peramivir is a novel influenza neuraminidase inhibitor used for anti-influenza. In this article, a novel method was developed to determine peramivir in dog plasma using a derivatization treatment step to increase the retention time and enhance the signal intensity. The sample preparation consisted of a protein precipitation extraction followed by derivatization with 10M hydrochloric acid-methanol (10:90, v/v) and determined by liquid chromatography coupled with tandem mass spectrometry. The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 343→284 and m/z 299→152 were used to measure the derivative of peramivir and Ro 64-0802 (internal standard, an active metabolite of oseltamivir). The chromatographic separation was achieved using a ZORBAX RX-C8 (2.0mm×150mm×5μm) analytical column with an isocratic mobile phase composed of acetonitrile-water-formic acid (30:70:0.1, v/v/v, 0.2mL/min). The method was linear over a concentration range of 0.25-250ng/mL. The average intra-day/inter-day precision values were 4.04-8.17% and 3.02-7.08%, respectively, while the average accuracy value was 93.99-106.48%. This method has been successfully applied to the preclinical dog research of peramivir following intragastric administration.
帕拉米韦是一种新型的流感神经氨酸酶抑制剂,用于抗流感。在本文中,开发了一种新方法,通过衍生化处理步骤来增加保留时间并增强信号强度,从而在狗血浆中测定帕拉米韦。样品制备包括蛋白沉淀提取,然后用 10M 盐酸-甲醇(10:90,v/v)衍生化,并通过液相色谱-串联质谱法进行测定。采用正离子选择反应监测模式,用 m/z 343→284 和 m/z 299→152 的前体到产物离子的过渡来测量帕拉米韦和 Ro 64-0802(奥司他韦的活性代谢物,内标)的衍生物。采用 ZORBAX RX-C8(2.0mm×150mm×5μm)分析柱,以乙腈-水-甲酸(30:70:0.1,v/v/v,0.2mL/min)为等度流动相实现色谱分离。该方法在 0.25-250ng/mL 的浓度范围内呈线性。日内/日间精密度的平均 值分别为 4.04-8.17%和 3.02-7.08%,平均准确度 值为 93.99-106.48%。该方法已成功应用于狗经口给予帕拉米韦后的临床前研究。